Pancreatic Cancer Research

ResearcherUniversity Hospitals Birmingham NHS Foundation TrustActive in the last 2 years

S.S. Raza

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3052-7527; OpenAlex author ID A5031722569. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2024: 2 papers · 2025: none · 2026: 7 papers

Papers 9

  1. Colonization of bile with gammaproteobacteria is associated with reduced survival after surgery for pancreatic cancer in patients receiving gemcitabine-based a… Co-author DOI 10.1016/j.ejso.2026.111396↗
  2. Effect of duration of neoadjuvant therapy on pancreatic cancer outcomes: a systematic review and meta-analysis. Co-author DOI 10.1016/j.hpb.2025.12.018↗
  3. Intention to treat outcomes following management of locally advanced pancreatic ductal adenocarcinoma with curative intent: single centre cohort study. Co-author DOI 10.1016/j.hpb.2026.06.008↗
  4. Temporary Mesocaval Shunt: A Surgical Strategy to Facilitate Pancreatic Cancer Resection With Complex Vascular Involvement. Co-author DOI 10.1111/ans.70977↗
  5. Neoadjuvant Chemoradiotherapy Versus Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis of Randomised Contro… Co-author DOI 10.1245/s10434-026-20319-7↗
  6. ASO Author Reflections: It is Time to Define an Optimal Duration of Neoadjuvant Treatment in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20436-3↗
  7. ASO Visual Abstract: Neoadjuvant Chemoradiotherapy versus Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis… Co-author DOI 10.1245/s10434-026-20533-3↗
  8. Can preoperative Carbohydrate Antigen 19-9 predict metastatic pancreatic cancer? Results of a systematic review and meta-analysis. Co-author DOI 10.1016/j.hpb.2024.01.017↗
  9. Staging Computed Tomography Parameters Predict the Need for Vein Resection during Pancreaticoduodenectomy in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/diagnostics14020135↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David Christopher Bartlett · 9 shared papers, 2024–2026 · strength 2.29
  2. Robert Peter Sutcliffe · 9 shared papers, 2024–2026 · strength 2.29
  3. Nikolaos A. Chatzizacharias · 9 shared papers, 2024–2026 · strength 2.29
  4. Keith John Roberts · 8 shared papers, 2024–2026 · strength 2.11
  5. Shahin Hajibandeh · 5 shared papers, 2024–2026 · strength 1.36
  6. Shahab Hajibandeh · 5 shared papers, 2024–2026 · strength 1.36
  7. Lewis A Hall · 2 shared papers, 2026 · strength 0.46
  8. Peter Lawrence Zaki Labib · 2 shared papers, 2026 · strength 0.46
  9. Sarah F. Powell-Brett · 2 shared papers, 2026 · strength 0.46
  10. Moath Alarabiyat · 2 shared papers, 2026 · strength 0.46
  11. Charlotte Terry · 1 shared paper, 2026 · strength 0.28
  12. Nabeel Merali · 1 shared paper, 2026 · strength 0.28
  13. Adam Enver Frampton · 1 shared paper, 2026 · strength 0.28
  14. Rupaly Pandé · 1 shared paper, 2024 · strength 0.20
  15. James S. Good · 1 shared paper, 2026 · strength 0.18
  16. Shivan Sivakumar · 1 shared paper, 2026 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.